Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 30.09.2026 FTEI.LN IE000TIZ5AP4  300,002.00 EUR   6,200,335.39   20.668  ...

GALASHIELS & MARLOW, VK--(BUSINESS WIRE)--Kyowa Kirin International, een volledige dochteronderneming van Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), heeft vandaag de ondertekening aangekondigd van een exclusieve distributieovereenkomst met Knight Therapeutics ('Knight') (TSX: GUD) voor de distributie van mogamulizumab in geselecteerde landen in Latijns-Amerika. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden ver...

GALASHIELS et MARLOW, Royaume-Uni--(BUSINESS WIRE)--Kyowa Kirin International, filiale à 100 % de Kyowa Kirin Co., Ltd. (TSE : 4151, Kyowa Kirin), a annoncé aujourd’hui avoir signé un accord de distribution exclusif avec Knight Therapeutics (« Knight ») (TSX : GUD) portant sur la distribution du mogamulizumab dans certains pays d’Amérique latine. Selon les termes de l’accord, Knight aura pour mission d’obtenir les autorisations réglementaires nécessaires pour commercialiser le mogamulizumab en...

GALASHIELS & MARLOW, GB--(BUSINESS WIRE)--Kyowa Kirin International, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die Unterzeichnung einer exklusiven Vertriebsvereinbarung mit Knight Therapeutics („Knight“) (TSX: GUD) über den Vertrieb von Mogamulizumab in ausgewählten Ländern Lateinamerikas bekannt. Gemäß den Vertragsbedingungen ist Knight dafür verantwortlich, die erforderlichen behördlichen Genehmigungen einzuholen und Mogamulizumab...

CHEVY CHASE, Md.--(BUSINESS WIRE)--Forbright, Inc. (Nasdaq: FRBT) (the "Company"), the parent company of wholly-owned subsidiary Forbright Bank, has scheduled the release of its third quarter 2026 financial results for Thursday, October 29, 2026, at approximately 6:00 a.m. ET. The earnings press release and investor presentation will be available on the Company’s Investor Relations website at ir.forbrightbank.com. Forbright, Inc. will host a conference call at 8:00 a.m. ET on October 29, 2026,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

BRATISLAVA, Slovakia--(BUSINESS WIRE)--Powerful Medical, developer of the PMcardio AI cardiology platform, and corpuls, Europe's leading manufacturer of monitor/defibrillator systems for prehospital emergency medical services, today announced a strategic partnership to integrate Powerful Medical's Queen of Hearts AI ECG model directly into the corpuls platform used by emergency care professionals in over 70 countries globally. Health care professionals recording a 12-lead ECG on a corpuls3 devi...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, has presented new data on delgocitinib cream in Chronic Hand Eczema (CHE) at the 35th European Academy of Dermatology and Venereology (EADV) Congress, held from 30 September to 3 October 2026 in Vienna, Austria. In total, six delgocitinib presentations feature in the company’s programme at the congress, including one oral presentation and five ePosters, spanning adults and adolescents, controlled clinica...

LILLE, França--(BUSINESS WIRE)--A Roquette apresentará seu portfólio completo de excipientes farmacêuticos, soluções de administração de fármacos e expertise técnica de ponta na CPHI Milão 2026 na Itália, onde a empresa receberá visitantes no estande 1A18 no salão de excipientes. No evento global deste ano, a Roquette destacará as principais marcas de produtos que apoiam o desempenho das formulações, a administração de fármacos centrada no paciente e a inovação biofarmacêutica, incluindo os éte...